Impairment of the p53 tumor suppressor network is thought to be involved in a large percentage of tumors either by mutations in the p53 gene or by increased expression of its major control system, the MDM2 (murine double minute 2; HDM2 for its human equivalent). It is important to realize that levels of p53 are subjected to an autoregulatory feedback loop by MDM2 as p53 upregulates MDM2 gene expression and MDM2 protein in turn binds to p53. MDM2 is an E3 ubiquitin ligase and transports p53 to the cytoplasm where it promotes p53 ubiquitination and degradation by the proteasome. In human cancer, increased levels of MDM2 are caused either by gene amplification, increased expression induced by activated p53, stabilization by an aberrantly spliced form of HDMX, or augmented translation. In addition to these mechanisms, functional single-nucleotide polymorphisms (SNP) such as the 1 at nucleotide 309 (SNP309) in the MDM2 gene can modulate MDM2 expression and cause increased tumor progression. Thus, mutations in the p53 gene or an increase in MDM2 protein impair the effectiveness of p53-dependent proapoptotic and cell-cycle arrest mechanisms and thereby favor the development of tumors. In addition, MDM2 has also p53-independent activities through interactions with proteins involved in controlling cell proliferation and survival. This concatenation of data indicated that disruption of the p53–MDM2 autoregulatory feedback loop as well as inhibition of MDM2 would be a suitable strategy for tumor therapy. In fact, Vassilev et al recently developed a class of small molecules, the nutlin-3, a tetra-substituted imidazolone, that occupy the p53-binding pocket in MDM2 and thereby preventing MDM2 binding to p53. Similarly, nutlin-3 also binds to and interferes with MDMX, another component of the p53 tumor surveillance pathway. This leads to a disruption of the autoregulatory feedback loop and consequently the p53 tumor suppressor network is fostered. Consistently, Vassilev et al further showed that nutlin-3 induces apoptosis especially in cancer cell lines with increased MDM2 expression which correlates well with in vivo antitumor efficacy of nutlin-3 (Figure 1).

An antitumor strategy that interferes with the p53–MDM2 feedback loop should therefore work best in tumors with wild type p53 (approximately 50% of all tumors) and increased MDM2 which suppresses functional active p53. On the other hand, such a strategy does not appear to be promising in tumors with a mutated p53 gene. In this issue of Circulation Research, Secchiero et al, however, report that nutlin-3 may have additional potent antitumor activities by a novel effect of this molecule on angiogenesis. This antiangiogenic effect of nutlin-3 might be an important widening of the possible therapeutic window for nutlin-3 as it is assumed that endothelial cells of blood vessels supplying even a tumor with mutations in p53 do in general not contain such p53 mutations. It is now clear that tumor growth and progression critically depend on an adequate blood supply. Moreover, antiangiogenic therapies have the advantage of not inducing tumor resistance. Thus, a nutlin-3 based antitumor therapy might also have potential in tumors containing a mutated and nonfunctioning p53 gene.

What are the underlying mechanisms for the antiangiogenic activity of nutlin-3? In this article the authors demonstrate that nutlin-3 has antiangiogenic activities via 3 different mechanisms: (1) by inhibiting endothelial cell migration, which seems to be the predominant effect; (2) by inducing cell cycle arrest; and (3) by increasing apoptotic tendency in endothelial cells. The authors also show that nutlin-3 treatment of endothelial cells leads to accumulation of p53, indicating that the effects of nutlin-3 in these cells are also related to its interference with the p53–MDM2 autoregulatory feedback loop (Figure 2). There are only few reports of a direct effect of p53 in endothelial cells. However, with respect to tumor cell migration an effect of p53 on cell

---

The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

From the Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University Vienna.

Correspondence to Bernd R. Binder, Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University Vienna, Schwarzspanierstr. 17, 1090, Austria. E-mail bernd.binder@meduniwien.ac.at

(Circ Res. 2007;100:13-14.)

© 2007 American Heart Association, Inc.

Circulation Research is available at http://circres.ahajournals.org

DOI: 10.1161/01.RES.0000255897.84337.38

---

Figure 1. The p53–MDM2 autoregulatory feedback loop in cancer (modified according to Harris): nutlin-3 inhibits increased MDM2 activity and thereby restores p53 levels.
motility has been demonstrated which is largely mediated through the regulation of Rho signaling, thereby controlling actin cytoskeletal organization (reviewed in20). One could speculate that in analogy to tumor cells a similar mechanism might be responsible for the effects in endothelial cells.

The data presented here by Secchiero et al are far from clinical applications and even the in vivo data are restricted to a Matrigel plug system in mice. Nevertheless, these data might open a new route for a broader application of nutlin-3 or other MDM2 antagonists7,21,22 not only for direct antitumor therapies but also for application in antiangiogenic regimens.23

Disclosures
None.

References
A Novel Application for Murine Double Minute 2 Antagonists: The p53 Tumor
Suppressor Network Also Controls Angiogenesis
Bernd R. Binder

Circ Res. 2007;100:13-14
doi: 10.1161/01.RES.0000255897.84337.38

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circres.ahajournals.org/content/100/1/13

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/